LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

2.86 0.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.84

Max

2.94

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+39.86% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.8M

1.1B

Vorige openingsprijs

2.51

Vorige sluitingsprijs

2.86

Nieuwssentiment

By Acuity

50%

50%

169 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 mrt 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mrt 2026, 22:36 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Government Rules Out Boots on the Ground in the Middle East

30 mrt 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mrt 2026, 21:00 UTC

Winsten

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mrt 2026, 20:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mrt 2026, 23:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 23:40 UTC

Marktinformatie

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mrt 2026, 23:36 UTC

Marktinformatie

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mrt 2026, 23:12 UTC

Marktinformatie

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mrt 2026, 22:49 UTC

Marktinformatie

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mrt 2026, 22:44 UTC

Marktinformatie

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mrt 2026, 22:43 UTC

Marktinformatie

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mrt 2026, 22:42 UTC

Marktinformatie

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mrt 2026, 22:18 UTC

Marktinformatie

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mrt 2026, 22:05 UTC

Marktinformatie

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mrt 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mrt 2026, 21:36 UTC

Acquisities, Fusies, Overnames

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mrt 2026, 21:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 21:25 UTC

Marktinformatie

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mrt 2026, 21:03 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 mrt 2026, 20:09 UTC

Winsten

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mrt 2026, 20:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

39.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  39.86%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

169 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat